MSB has delivered one of its stronger weekly performances in recent memory, gaining 17% to AUD 2.38, while short sellers have quietly trimmed exposure — a combination that makes the lending market the most interesting angle to watch right now.
The positioning picture is a study in gradual easing. Short interest — at 8.5% of free float — remains meaningfully elevated for an ASX-listed biotech, but the trend is moving against the bears. Shorts have fallen roughly 2.6% over the past month, retreating from a peak near 115 million shares in mid-June to around 108.6 million today. The borrow market reflects that shift: cost to borrow has dropped 35% over the past week to 1.27%, well below where it was sitting during the late-June squeeze pressure. Availability has also loosened, recovering to 42.7% from a tight low of around 36% two weeks ago — still firmly in "tight" territory relative to the broader market, but the direction is clearly moving toward less stress in the lending pool. Notably, the 52-week low for availability was near zero, a reminder of how compressed borrow conditions can get when sentiment turns sharply negative on this name.
The ORTEX short score — running at 79.5 — underscores just how short-heavy the positioning remains despite the recent relief. That score has barely moved over the past ten sessions, drifting slightly lower from 79.8 to 79.5, which tells a consistent story: the structural short base is stubborn even as the stock pushes higher. The days-to-cover reading of 36.4 reinforces that picture — at current trading volumes, unwinding the existing short position would take over a month, leaving bears heavily exposed to any sustained upward move.
The Street angle is constrained by stale data. The most recent analyst consensus — a mean price target of AUD 3.80 against the current AUD 2.38 — implies meaningful upside, but that data is now nearly 100 days old with no recent changes on record, so it should be treated cautiously rather than as a live signal. What the factor scores do confirm is a sharp divergence in character: the forward EPS estimate improvement ranks in the 90th percentile, while EPS surprise and momentum sit near the bottom of the universe. Mesoblast is a growth story that has not yet translated into earnings consistency — the EV/EBITDA multiple at 104x reflects exactly that tension between clinical promise and commercial reality. The price-to-book of 3.9x has expanded over the past month, tracking the stock's re-rating.
Institutional ownership adds a layer of structural context worth noting. Director Gregory George remains the dominant shareholder at just over 20% of shares, and JPMorgan and State Street both added to positions as recently as June, each adding around 4-5 million shares. That institutional accumulation runs against the short interest trend and helps explain why the borrow market has not tightened further — there is genuine long-side conviction anchoring the register. CEO Silviu Itescu trimmed 8.8 million shares in March, though that trade is now several months old and the stock has moved materially since.
Earnings are due August 27 — and the historical reaction pattern leans decidedly negative. The February 2026 result produced a one-day fall of 14.5%, with further weakness over the following five days. The June report generated a modest 1% gain the next day but gave back ground over the week. With the short score still near 80 and availability still tight at 43%, the setup heading into that print will be worth watching closely.
See the live data behind this article on ORTEX.
Open MSB on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
